The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture

Liver International

Volumn 33, Issue 1, 2013, Pages 127-136

  Hoh, Alexander ^a   Dewerth, Alexander ^a   Vogt, Fabian ^a   Wenz, Julia ^a   Baeuerle, Patrick A ^b   Warmann, Steven W ^a   Fuchs, Joerg ^a   Armeanu Ebinger, Sorin ^a  

^a University Children's Hospital Tuebingen   (Germany)

^b Amgen Research GmbH   (Germany)

Author keywords

T cells; EpCAM; Hepatoblastoma; Immune therapy; Paediatric hepatocellular carcinoma; Therapeutic antibodies

Indexed keywords

HISTONE DEACETYLASE INHIBITOR;

ARTICLE; CELL ACTIVITY; CELL CULTURE; CELL EXPANSION; CELL INTERACTION; CELL TRANSFER; CELL VIABILITY; CHILD; CHILDHOOD CANCER; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; EX VIVO STUDY; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; INCUBATION TIME; LIVER CELL CARCINOMA; MALE; NK T CELL LYMPHOMA; PRESCHOOL CHILD; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR CELL DESTRUCTION; TUMOR SPHEROID; WESTERN BLOTTING;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL SURVIVAL; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DIPHOSPHONATES; HEPATOBLASTOMA; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMIDAZOLES; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; MICROSCOPY, FLUORESCENCE; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SINGLE-CHAIN ANTIBODIES; SPHEROIDS, CELLULAR; T-LYMPHOCYTES;

EID: 84870788833     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12011     Document Type: Article

References (48)

1. Czauderna P, Mackinlay G, Perilongo G, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 2002; 20: 2798-804.
2. Ishak KG, Glunz PR. Hepatoblastoma and hepatocarcinoma in infancy and childhood. Report of 47 cases. Cancer 1967; 20: 396-422.
3. Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. J Clin Oncol 2002; 20: 2789-97.
4. Weinberg AG, Finegold MJ. Primary hepatic tumors of childhood. Hum Pathol 1983; 14: 512-37.
5. Czauderna P, Roebuck DJ, Von Schweinitz D, Plaschkes J. Surgical treatment of hepatoblastoma in children. Pediatr Radiol 2006; 36: 187-91.
6. Chen JC, Chen CC, Chen WJ, et al. Hepatocellular carcinoma in children: clinical review and comparison with adult cases. J Pediatr Surg 1998; 33: 1350-4.
7. Litten JB, Tomlinson GE. Liver tumors in children. Oncologist 2008; 13: 812-20.
8. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
9. von Schweinitz D. Hepatoblastoma: recent developments in research and treatment. Semin Pediatr Surg 2012; 21: 21-30.
10. Viey E, Fromont G, Escudier B, et al. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol 2005; 174: 1338-47.
11. Kondo M, Sakuta K, Noguchi A, et al. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008; 10: 842-56.
12. Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000; 18: 975-1026.
13. Meraviglia S, El Daker S, Dieli F, Martini F, Martino A. gammadelta T cells cross-link innate and adaptive immunity in Mycobacterium tuberculosis infection. Clin Dev Immunol 2011; 2011: 587315.
14. Morita CT. LEE H K, LESLIE D S, TANAKA Y, BUKOWSKI J F, MARKER-HERMANN E. Recognition of nonpeptide prenyl pyrophosphate antigens by human gammadelta T cells. Microbes Infect 1999; 1: 175-86.
15. Rincon-Orozco B, Kunzmann V, Wrobel P, et al. Activation of V gamma 9V delta 2 T cells by NKG2D. J Immunol 2005; 175: 2144-51.
16. Tanaka Y. NIEVES E, BRENNER M B, BLOOM B R. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 1995; 375: 155-8.
17. Dieli F, Troye-Blomberg M, Ivanyi J, et al. Granulysin-dependent killing of intracellular and extracellular Mycobacterium tuberculosis by Vgamma9/Vdelta2 T lymphocytes. J Infect Dis 2001; 184: 1082-5.
18. Dieli F, Gebbia N, Poccia F, et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003; 102: 2310-1.
19. Doi I. Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann 1976; 67: 1-10.
20. Pietsch T, Fonatsch C, Albrecht S, Maschek H, Von Schweinitz D. Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest 1996; 74: 809-18.
21. Armeanu-Ebinger S, Wenz J, Seitz G, et al. Characterisation of the Cell Line HC-AFW1 Derived from a Pediatric Hepatocellular Carcinoma. PLoS ONE 2012; 7: e38223.
22. Ebinger M, Ahlers J, et al. High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia. Leukemia Res 2010; 34: 1139-42.
23. Lieber J, Ellerkamp V, Wenz J, et al. Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells. Pediatr Surg Int 2012; 28: 149-59.
24. Herrmann I, Friedrich M, et al. Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. PLoS ONE 2010; 5: e13474.
25. Marschner N, Ruttinger D, Zugmaier G, et al. Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy. Urol Int 2010; 85: 386-95.
26. Schmidt M, Dittrich C, et al. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol 2010; 21: 275-82.
27. Urban EM, Chapoval AI, Pauza CD. Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells. Clin Dev Immunol 2010; 2010; 732893. doi:10.1155/2010/732893.
28. Cairo S, Armengol C, de Reynies A, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008; 14: 471-84.
29. Armeanu S, Bitzer M, Lauer UM, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65: 6321-9.
30. Pfeiffer M, Seitz G, Ruck P, et al. CD155 is involved in NK-cell mediated lysis of human hepatoblastoma in vitro. Front Biosci (Elite Ed) 2011; 3: 1456-66.
31. Sevmis S, Karakayali H, Ozcay F, et al. Liver transplantation for hepatocellular carcinoma in children. Pediatr Transplant 2008; 12: 52-6.
32. Zsiros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 2010; 28: 2584-90.
33. Inaba H, Handgretinger R, Furman W, Hale G, Leung W. Allogeneic graft-versus-hepatoblastoma effect. Pediatr Blood Cancer 2006; 46: 501-5.
34. Wilhelm M, Kunzmann V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102: 200-6.
35. Chaleff S, Otto M, Barfield RC, et al. A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy 2007; 9: 746-54.
36. Alexander AA, Maniar A, Cummings JS, et al. Isopentenyl pyrophosphate-activated CD56 + gamma}{delta T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res 2008; 14: 4232-40.
37. Petsch S, Gires O, Ruttinger D, et al. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110. MAbs 2011; 3: 31-7.
38. Patriarca C, Macchi RM, Marschner AK, Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 2011; 38: 68-75.
39. Yamashita T, Forgues M, Wang W, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008; 68: 1451-61.
40. Preithner S, Elm S, Lippold S, et al. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol 2006; 43: 1183-93.
41. Tokuyama H, Hagi T, Mattarollo SR, et al. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs-rituximab and trastuzumab. Int J Cancer 2008; 122: 2526-34.
42. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349-52.
43. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202.
44. Butler LM, Zhou X, Xu WS, et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 2002; 99: 11700-5.
45. Kobayashi H, Tanaka Y, Shimmura H, Minato N, Tanabe K. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma. Anticancer Res 2010; 30: 575-9.
46. Kobayashi H, Tanaka Y, Yagi J, Minato N, Tanabe K. Phase I/II study of adoptive transfer of gammadelta T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol Immunother 2011; 60: 1075-84.
47. Nicol AJ, Tokuyama H, Mattarollo SR, et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 2011; 105: 778-86.
48. Yoshida Y, Nakajima J, Wada H, Kakimi K. gammadelta T-cell immunotherapy for lung cancer. Surg Today 2011; 41: 606-11.